publication date: Jul. 31, 2014
NCI CTEP-Approved Trials for the Month of July
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
ADVL1314: A Phase 1 Study of Eribulin Mesylate (E7389, IND#116,292), a Novel Microtubule Targeting Chemotherapeutic Agent in Children with Refractory or Recurrent Solid Tumors (Excluding CNS), Including Lymphomas. COG Phase 1 Consortium; Schafer, Eric Stephen. (832) 825-4241
ADVL1315: A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA, IND# TBD) in Children with Recurrent or Refractory Solid Tumors. COG Phase 1 Consortium; Geller, James Ian. (513) 636-6312
EA2131: A Phase I and Randomized, Double-Blinded Phase II Study of Nab-Paclitaxel/Gemcitabine Plus AZD1775 or Placebo in Treatment-Naïve Metastatic Adenocarcinoma of the Pancreas. ECOG-ACRIN Cancer Research Group; Chee, Cheng Ean. (216) 844-8609
9604: Perfusion CT as Predictive Biomarker in a Phase II Study of Ziv-Aflibercept in Patients with Advanced Pancreatic Neuroendocrine Tumors. MD Anderson Cancer Center; Yao, James C. (713) 792-2828
S1300: A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-Squamous NSCLC Patients Who Have Progressed Systemically After Previous Clinical Benefit From Crizotinib Monotherapy. SWOG; Camidge, David Ross. (720) 848-0449
S1320: A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma. SWOG; Algazi, Alain Patrick. (415) 353-7552
ARST1321: … Continue reading CCL July – NCI CTEP-Approved Trials for the Month of July
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.